Phoenix Wealth Advisors’s Biogen BIIB Stock Holding History

Phoenix Wealth Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-263	Closed	-$74K	–	150
2021 Q3	$74K	Hold	263	–	–	0.06%	164
2021 Q2	$91K	Hold	263	–	–	0.07%	159
2021 Q1	$73K	Hold	263	–	–	0.06%	165
2020 Q4	$64K	Buy	+263	New	+$67.8K	0.05%	176

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Phoenix Wealth Advisors's BIIB Position: Q4 2021 in Review

Phoenix Wealth Advisors sold out of Biogen (BIIB) in Q4 2021, closing a stake of 263 shares — an estimated $74K sold.

Phoenix Wealth Advisors first reported a position in BIIB in Q4 2020 and held it in 4 quarters. The position peaked at $91K in Q2 2021. 1,009 funds tracked by Wall St. Rank hold BIIB as of Q4 2021.

Phoenix Wealth Advisors reported no remaining Biogen position as of Q4 2021 after selling out during the quarter.
Phoenix Wealth Advisors sold 263 Biogen shares in Q4 2021, an estimated $74K.
Phoenix Wealth Advisors first reported a position in Biogen in Q4 2020 and held it in 4 quarters.
Phoenix Wealth Advisors's Biogen position peaked at $91K in Q2 2021.
1,009 funds tracked by Wall St. Rank held Biogen as of Q4 2021.

Based on Phoenix Wealth Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.